Cure Ventures

Partner with over three decades in neuroscience drug discovery. Founding scientist and Chief Scientific Officer at Sage Therapeutics, contributing to approved CNS drugs Zulresso and Zurzuvae, with prior roles at Lundbeck and Wyeth.

Partner with over ten years in academic licensing and venture investing. Previously spent over six years on the Omega Funds investment team and worked at MIT's Technology Licensing Office.

Partner and Chief Technology Officer at Cure Ventures leading bioinformatics efforts, with 25 years combining analytical chemistry and computer science to accelerate drug discovery. Previously co-founded Precision Health Software and worked with Third Rock Ventures portfolio companies.

Managing Partner and Co-Founder of Cure Ventures with over 20 years investing in venture and alternative asset funds. Previously advised Polaris Partners and held roles at TIFF Investment Management, the Alaska Permanent Fund and GF Private Equity Group.

Partner and Chief Financial Officer overseeing finance and operations at the firm and portfolio companies. Previously VP of Finance at Bain Capital and a finance manager at Absolute Return Capital, with seven years at Ernst & Young.

Partner with over two decades in CNS drug discovery and development, contributing to medicines such as Lexapro, Vyvanse and Zulresso. Previously CEO of ABIO-X and CEO/Chief Innovation Officer at Sage Therapeutics.

Partner with over three decades in biotech focused on translating scientific discoveries into therapies. Co-founded Sporos Bioventures as CSO and previously spent 12 years at AVEO Oncology including as Chief Scientific Officer.

Partner with over 13 years in drug discovery at the intersection of genetics, genomics and bioinformatics. Previously a Senior Director at Bristol Myers Squibb and led translational bioinformatics at Fog Pharma.

Kenzie Maclsaac is a Partner at Cure Ventures. Their areas of focus include computational immunology, immuno-oncology, clinical genomics, and statistical analysis of high-throughput biological data.

Partner with over 20 years in drug discovery and development across small molecules, biologics and cell therapies, with deep expertise in oncology and metabolic diseases. Previously held leadership roles at Novartis, AVEO and Millennium Pharmaceuticals.

Associated with portfolio company Tasca Therapeutics, which works on post-translational modification to expand the druggable proteome.

Managing Partner with three decades in life sciences spanning corporate development and venture investing. Previously Managing Member and President of Omega Funds and founded MVM Life Science Partners' US operations.

Director of Finance with nearly two decades across biotech, sports and public accounting, focused on scalable financial processes for portfolio companies. Previously Director of Accounting at Prime Medicine and supported Tortugas Neuroscience.

Senior Associate focused on company creation. Earned his PhD at Johns Hopkins under Nobel Laureate Carol Greider studying telomere biology, and was previously an associate at Third Rock Ventures.

Executive Assistant and Office Manager supporting the team with calendar and meeting management, event planning and project coordination. Previously a Finance Associate at Easterly Partners Group.

Senior Associate with over a decade of academic and industry research experience. Completed her PhD in neuroscience in Munich studying microglia in frontotemporal dementia and worked in clinical operations at Genentech.

Senior Associate with over 10 years of research experience, involved in sourcing deals, due diligence and company creation. Earned her PhD in Molecular and Cell Biology at the University of Connecticut studying cell death and cancer biology.

Associate with over ten years in biomedical research, previously a consultant at ClearView Healthcare Partners. Earned his PhD in cancer biology at the University of Chicago and interned with ARCH Venture Partners.